AI-powered cardiac MRI solution gains FDA clearance

HeartVista, a Los Altos, California-based healthcare technology company, has received FDA clearance for its AI-powered One Click cardiac MRI solution.

According to HeartVista, One Click removes many of the limitations of cardiac MRI and makes it “simple, time-efficient, affordable and highly consistent.”

“Patients across the country now have access to the only AI-guided cardiac MRI exam, which will deliver continuous imaging via an automated process, minimize errors and simplify scan operation,” Itamar Kandel, CEO of HeartVista, said in a prepared statement. “Our AI solution generates definitive, accurate and actionable real-time data for cardiologists. We believe it will elevate the standard of care for cardiac imaging, enhance patient experience and access and improve patient outcomes.”

Kandel also highlighted a study published by the New England Journal of Medicine in June 2019, noting that cardiac MRI was found to be “the gold standard for cardiac diagnosis, even when compared against invasive alternatives.”

Michael Walter
Michael Walter, Managing Editor

Michael has more than 18 years of experience as a professional writer and editor. He has written at length about cardiology, radiology, artificial intelligence and other key healthcare topics.

Around the web

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.

The imaging manufacturer expects to spend between $227 million and $340 million on tariff mitigation efforts, leaders said Wednesday. 
 

U.S.-China tariffs will have a $226M to $340M net impact on its bottom line in 2025, even after substantial mitigation efforts, the imaging manufacturer estimates.